Celcuity Inc. (NASDAQ:CELC) Short Interest Up 6.4% in January

Celcuity Inc. (NASDAQ:CELC) was the recipient of a significant increase in short interest in the month of January. As of January 31st, there was short interest totalling 3,330,000 shares, an increase of 6.4% from the January 15th total of 3,130,000 shares. Based on an average trading volume of 283,600 shares, the short-interest ratio is presently 11.7 days.

Institutional Investors Weigh In On Celcuity

Large investors have recently made changes to their positions in the company. nVerses Capital LLC bought a new stake in shares of Celcuity in the 3rd quarter valued at approximately $33,000. Prospera Private Wealth LLC bought a new stake in Celcuity during the third quarter worth approximately $35,000. Summit Investment Advisors Inc. boosted its position in Celcuity by 49.5% during the fourth quarter. Summit Investment Advisors Inc. now owns 3,421 shares of the company’s stock worth $45,000 after purchasing an additional 1,132 shares during the period. Aquatic Capital Management LLC bought a new stake in Celcuity during the fourth quarter worth approximately $50,000. Finally, Values First Advisors Inc. bought a new stake in Celcuity during the third quarter worth approximately $86,000. Institutional investors own 63.33% of the company’s stock.

Celcuity Stock Down 0.9 %

Shares of CELC traded down $0.12 during trading hours on Tuesday, reaching $12.76. The company’s stock had a trading volume of 230,522 shares, compared to its average volume of 229,775. The firm has a market cap of $473.78 million, a price-to-earnings ratio of -4.89 and a beta of 0.73. The company has a 50 day moving average of $12.26 and a two-hundred day moving average of $14.10. Celcuity has a 1-year low of $10.35 and a 1-year high of $22.19. The company has a quick ratio of 10.36, a current ratio of 10.35 and a debt-to-equity ratio of 0.65.

Analyst Ratings Changes

A number of equities analysts recently weighed in on CELC shares. Needham & Company LLC lifted their price target on Celcuity from $23.00 to $29.00 and gave the stock a “buy” rating in a research note on Thursday, February 6th. HC Wainwright reissued a “buy” rating and issued a $27.00 price target on shares of Celcuity in a research note on Friday, November 15th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Celcuity has a consensus rating of “Buy” and an average target price of $30.17.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.